# A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

> **NCT06954961** · PHASE3 · RECRUITING · sponsor: **InventisBio Co., Ltd** · enrollment: 640 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** D-0502
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT06954961
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-15
- **Primary completion:** 2026-11-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 640 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954961, "A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06954961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*